[Role of adriamycin in the therapy of bone sarcomas].
The improvement of bone sarcomas prognosis during the last fifteen years (60% disease free survival at 4 years for osteogenic sarcoma, 50% for Ewing's sarcoma) is due in a large measure, to introduction of chemotherapy. ADR is a very effective agent in the treatment of those tumors but its use is limited by its cardiotoxicity. In the current chemotherapy protocols, the best results are obtained with the combination of intensive ADR-HDMTX, ADR-CDDP in osteogenic sarcoma, and ADR-ACD-CTX in Ewing's sarcoma. The ADR-Ifosfamide association seems also to be promising.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D011184:Postoperative Period; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000601:surgery
D004317:Doxorubicin
Place de l'adriamycine dans le traitement des sarcomes osseux.